Jazz Stock Soars 8%, Adding $1.1 Billion, After It Raises 2026 Revenue Forecast

The drugmaker lifted its full-year sales outlook even as a $754 million acquired-research charge pushed the quarter to a loss.

Share
Jazz Stock Soars 8%, Adding $1.1 Billion, After It Raises 2026 Revenue Forecast

Jazz Pharmaceuticals, which makes medicines for sleep disorders, epilepsy and cancer, saw its shares climb 7.72% to $230.99 in Tuesday trading, as of 10:20 a.m. ET, adding about $1.1 billion in market value. The rally followed Monday's SEC filing, which raised the company's 2026 revenue outlook.

Record sales, then a loss

Quarterly sales of $1,243.0 million rose 10%. A $754 million acquired-research charge tied to the Actio deal still left Jazz with a $483.4 million net loss.

The charge works out to $11.32 per share, the company reported, and it drove the quarter's loss.

On Monday's earnings call, management flagged that a rival small cell lung cancer drug launch will be a 2027 headwind for Jazz's own lung cancer drug.

A pivot toward cancer drugs

Jazz sells Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for severe seizure disorders, and cancer drugs including Ziihera, Modeyso, Zepzelca and Rylaze. Xywav made up 41% of net product sales in 2025, followed by Epidiolex at 26%.

The company has been moving toward oncology through the Actio acquisition and the launch of Ziihera, while its older sleep franchise faces pressure.

Biggest gain since February

The stock was on pace for its biggest one-day gain since Feb. 25, when it rose 13.2%. Shares were up about 26% for the year at Monday's close, against about 10% for the S&P 500.

Monday's call put the 2027 lung cancer launch from a rival on the table, even as the 2026 outlook went up.

Sources

More on Jazz Pharmaceuticals

All Jazz Pharmaceuticals (JAZZ) coverage →